Summary
Merck & Co., Inc. reported strong financial performance for the third quarter and first nine months of 2011, showcasing significant year-over-year improvements in net income and earnings per share. Revenue growth was driven by key pharmaceutical products like Januvia, Janumet, and Singulair, alongside robust performance in the Animal Health segment. The company also saw a positive impact from foreign exchange rates. Despite ongoing restructuring costs related to the Merck-Schering-Plough integration, which are expected to yield substantial future savings, the company demonstrated solid operational execution. Merck continues to navigate a complex regulatory and competitive landscape, including ongoing litigation and patent expiries for some established products. However, strategic initiatives such as the acquisition of Inspire Pharmaceuticals and pipeline advancements, including regulatory filings and approvals for new indications, position the company for continued growth. The company's financial health is further supported by strong operating cash flows and a disciplined approach to capital allocation, including share repurchases and dividend payments.
Financial Highlights
50 data points| Revenue | $12.02B |
| Cost of Revenue | $4.35B |
| Gross Profit | $7.67B |
| R&D Expenses | $1.95B |
| SG&A Expenses | $3.34B |
| Interest Expense | $176.00M |
| Net Income | $1.69B |
| EPS (Basic) | $0.55 |
| EPS (Diluted) | $0.55 |
| Shares Outstanding (Basic) | 3.07B |
| Shares Outstanding (Diluted) | 3.09B |
Key Highlights
- 1Net income attributable to Merck & Co., Inc. increased substantially to $1.69 billion for Q3 2011 ($0.55 EPS) and $4.76 billion for the first nine months ($1.53 EPS), representing significant improvements over the prior year periods.
- 2Worldwide sales grew 8% in Q3 2011 to $12.0 billion and 5% for the nine-month period to $35.8 billion, driven by strong performance in pharmaceuticals (Januvia, Janumet, Singulair) and Animal Health.
- 3The company is actively managing restructuring costs associated with the merger integration, with anticipated annual savings of $4.0 billion to $4.6 billion upon completion.
- 4Merck completed the acquisition of Inspire Pharmaceuticals for approximately $420 million in May 2011, expanding its ophthalmic product portfolio.
- 5Key products like Januvia and Janumet showed robust growth, with Januvia sales up 41% in Q3 and Janumet sales up 42%.
- 6The company continues to advance its R&D pipeline, with recent approvals and submissions, including for Juvisync and Zoely, and progress in Phase III trials for several promising candidates.
- 7Merck maintained a strong liquidity position with $18.0 billion in cash and investments at September 30, 2011, and generated $9.2 billion in cash from operating activities for the first nine months.